- Trials with a EudraCT protocol (153)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
153 result(s) found for: Mantle.
Displaying page 1 of 8.
EudraCT Number: 2007-001108-19 | Sponsor Protocol Number: SAKK 36/06 | Start Date*: 2008-09-23 | |||||||||||
Sponsor Name:SAKK | |||||||||||||
Full Title: Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol S... | |||||||||||||
Medical condition: Traitement des lymphomes du manteau en deuxième ou troisième ligne (1ère ou 2nd rechute) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012807-25 | Sponsor Protocol Number: IIL-MCL0208 | Start Date*: 2010-01-28 | ||||||||||||||||||||||||||
Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS | ||||||||||||||||||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A... | ||||||||||||||||||||||||||||
Medical condition: Mantel cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) PT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011433-27 | Sponsor Protocol Number: ML22489 | Start Date*: 2009-11-04 | |||||||||||
Sponsor Name:Roche Romania SRL | |||||||||||||
Full Title: A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000548-33 | Sponsor Protocol Number: LyMa101 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004628-31 | Sponsor Protocol Number: FIL_V-RBAC | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) | |||||||||||||
Medical condition: Mantle Cell Lymphoma in elderly patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003893-17 | Sponsor Protocol Number: SAKK36/13 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:SAKK, Swiss Group for Clinical Cancer Research | ||||||||||||||||||
Full Title: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial | ||||||||||||||||||
Medical condition: Histologically confirmed mantle cell lymphoma in need of systemic treatment Refractory or relapsed disease after pretreatment of non-bortezomib containing chemotherapy including high-dose therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002117-28 | Sponsor Protocol Number: ACE-LY-004 | Start Date*: 2015-05-06 | |||||||||||
Sponsor Name:Acerta Pharma B.V. | |||||||||||||
Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001500-39 | Sponsor Protocol Number: LM01 | Start Date*: 2005-09-06 | |||||||||||
Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI | |||||||||||||
Full Title: A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma | |||||||||||||
Medical condition: treatment of patients with Mantle cell Lymphoma with tha combination R-HyperCVAD | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015909-39 | Sponsor Protocol Number: INT5909 | Start Date*: 2009-12-02 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly | |||||||||||||
Medical condition: Mantle-cell lymphoma (MCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005439-41 | Sponsor Protocol Number: PLRG-10/ML29157 | Start Date*: 2017-08-13 | |||||||||||
Sponsor Name:Polish Lymphoma Research Group (PLRG) | |||||||||||||
Full Title: EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE C... | |||||||||||||
Medical condition: Molecular relapse after the first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma (MCL) patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005541-36 | Sponsor Protocol Number: NLG-MCL6 | Start Date*: 2014-11-27 | |||||||||||
Sponsor Name:Nordic Lymphoma Group | |||||||||||||
Full Title: A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma. | |||||||||||||
Medical condition: Relapsed/refractory mantle cell lymphoma, | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004158-17 | Sponsor Protocol Number: GELTAMO-IMCL-2015 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea) | |||||||||||||
Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma. | |||||||||||||
Medical condition: Mantle Cell Lyphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004910-37 | Sponsor Protocol Number: OASIS-II | Start Date*: 2021-05-11 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma | |||||||||||||
Medical condition: Untreated mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001557-85 | Sponsor Protocol Number: 5.0 | Start Date*: 2011-08-22 | |||||||||||
Sponsor Name:Nordic Lymphoma Group | |||||||||||||
Full Title: NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial | |||||||||||||
Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Temporarily Halted) DK (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004039-30 | Sponsor Protocol Number: MCL5(MARiT) | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:PLymouth Hospitals NHS Trust | |||||||||||||
Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000711-88 | Sponsor Protocol Number: PCI-32765MCL2001 | Start Date*: 2012-09-13 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progres... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) GB (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001363-12 | Sponsor Protocol Number: TRIANGLE | Start Date*: 2016-03-24 | |||||||||||||||||||||
Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III | |||||||||||||||||||||||
Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial | |||||||||||||||||||||||
Medical condition: Generalized mantle cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001430-16 | Sponsor Protocol Number: 3066K1-305-WW | Start Date*: 2005-04-20 |
Sponsor Name:Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development | ||
Full Title: An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphom... | ||
Medical condition: Mantle Cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002150-64 | Sponsor Protocol Number: MCL 03 | Start Date*: 2004-12-22 |
Sponsor Name:Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology | ||
Full Title: Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma | ||
Medical condition: relapsed mantle cell lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002935-30 | Sponsor Protocol Number: 20-01434 | Start Date*: 2023-01-20 | |||||||||||
Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz | |||||||||||||
Full Title: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphom... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
